OncoSil Flags Isolated Administrative Lapse in Director Interest Disclosure

OncoSil Medical Ltd ( (AU:OSL) ) has shared an announcement.

OncoSil Medical has disclosed a late lodgement of an Appendix 3Y relating to CEO and managing director Nigel Lange, reflecting the lapse and cancellation of certain performance rights and employee loan-funded shares in line with their terms. The company attributed the delay to an administrative oversight, stressed that directors understand their disclosure obligations under ASX Listing Rules, cited existing securities trading policies, and characterised the event as an isolated incident, indicating confidence in its current compliance controls.

The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.54 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.

More about OncoSil Medical Ltd

OncoSil Medical Ltd is a global medical device company focused on interventional oncology, developing targeted intratumoural therapies using Phosphorous-32 microparticles alongside chemotherapy to improve outcomes for cancer patients. Its flagship OncoSil device treats unresectable locally advanced pancreatic cancer by delivering high-dose radiation directly into tumours while limiting exposure to surrounding organs, and holds CE Marking with approvals in more than 30 markets, including key European countries, the UK, Türkiye and Israel.

Average Trading Volume: 64,838

Technical Sentiment Signal: Sell

Current Market Cap: A$16.88M

See more data about OSL stock on TipRanks’ Stock Analysis page.